Markets:

Overview

News

Currencies

International

Treasuries

Passage Bio, Inc. - Common Stock (NQ:PASG)

4.700 +0.370 (+8.55%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Passage Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Passage Bio's Earnings: A Preview ↗

March 03, 2023

Via Benzinga

Passage Bio to Present at Cowen 43rd Annual Health Care Conference

February 28, 2023

From Passage Bio

Via GlobeNewswire

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

February 27, 2023

From Passage Bio

Via GlobeNewswire

Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

February 24, 2023

From Passage Bio

Via GlobeNewswire

Expert Ratings for Passage Bio ↗

December 15, 2022

Via Benzinga

Passage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage Disorder ↗

December 14, 2022

Via Benzinga

Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

February 15, 2023

From Passage Bio

Via GlobeNewswire

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 20, 2023

From Passage Bio

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

December 15, 2022

It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 14, 2022

Via Benzinga

Passage Bio: Q1 Earnings Insights ↗

May 16, 2022

Passage Bio (NASDAQ:PASG) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For May 16, 2022 ↗

May 16, 2022

Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.

Via Benzinga

Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

December 14, 2022

From Passage Bio

Via GlobeNewswire

Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 10, 2022

From Passage Bio

Via GlobeNewswire

Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day

November 08, 2022

From Passage Bio

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022 ↗

November 08, 2022

Upgrades

Via Benzinga

Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022

November 03, 2022

From Passage Bio

Via GlobeNewswire

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 14, 2022

From Passage Bio

Via GlobeNewswire

Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer

October 10, 2022

From Passage Bio

Via GlobeNewswire

Newman Ferrara LLP Announces Corporate Governance Investigations of Passage Bio, Inc. (PASG)

September 07, 2022

From Newman Ferrara LLP

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 16, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 12, 2022

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 11, 2022

Via Benzinga

Passage Bio Commences Initial-Stage Brain Disorder Study ↗

August 11, 2022

Passage Bio (NASDAQ: PASG) has dosed the first patient in the global Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin...

Via Benzinga

Preview: Passage Bio's Earnings ↗

August 03, 2022

Passage Bio (NASDAQ:PASG) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that Passage Bio...

Via Benzinga

Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

July 28, 2022

From Passage Bio

Via GlobeNewswire

This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday ↗

August 04, 2022

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.

Via Benzinga

Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session ↗

August 03, 2022

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 08, 2022

Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million.

Via Benzinga

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More ↗

May 16, 2022

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.